Company intelligence / Profile preview

veMico

Worthing, West Sussex, United Kingdomvemico.co.uk ↗

Ownership: Private
Development stage: Other

Overview

veMico develops innovative postbiotic solutions that modulate the gut microbiome and target immune receptors to strengthen gut barrier function, enhance immune resilience, and address modern lifestyle-related conditions. Their approach is based on over 20 years of expertise in human-microbe interactions, with a focus on clinically validated, orally delivered products leveraging Bifidobacterium spp. derived signalling molecules for targeted immune modulation.

Therapeutic areas: GastroenterologyImmunology
Modalities: PostbioticMicrobial therapy (specifically, microbiome-derived signalling molecules)Orally delivered products
Industry: Biotech

Drug pipeline

2 assets

Y GUT sensitive

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on veMico.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on veMico.

Explore the full profile